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University of Bergen and 4) Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, NorwayAbstractPyogenic streptococci cause signiﬁcant morbidity and mortality, and the incidence of invasive group C and G streptococcal disease appears to
be increasing. In this retrospective study we describe the epidemiological characteristics of invasive group A, C and G, along with non-invasive
group C and G streptococcal infections in Western Norway from 1999 to 2013. A total of 512 invasive streptococcal infections were
identiﬁed, of these 297 (58%) were group A (GAS), 24 (5%) group C (GCS) and 188 (37%) group G streptococci (GGS). In the non-
invasive group, 4935 GCS and GGS-infections were identiﬁed. GCS and GGS were treated as one group (GCGS) for statistical purposes.
All microbial categories displayed increasing incidence with age, seasonal variation and a male predominance. The incidence of invasive GCGS
infections increased signiﬁcantly from 1.4/100 000 inhabitants in 1999 to 6.3/100 000 in 2013 (p <0.001). Conversely, the annual rates of
invasive GAS infection exhibited marked ﬂuctuations, ranging from 2.7/100 000 (2000) to 8.3/100 000 (1999), but no signiﬁcant temporal
trends were observed. The incidence of non-invasive GCGS infections decreased signiﬁcantly during the study period (p <0.001). The
most frequently encountered emm-types among the 209 iGAS-isolates analysed were emm1 (24%), emm3 (14%) and emm28 (14%);
whereas stG643 (19%), stG485 (15%) and stG6 (13%) were most prevalent among the 122 iGCGS-isolates available for typing.
The increasing burden of invasive β-haemolytic streptococcal disease in our community calls for sustained attentiveness to the clinical and
molecular aspects of GAS, GCS and GGS infections.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: Oddvar.Oppegaard@helse-bergen.noIntroductionThe resurgence of invasive β-haemolytic streptococcal disease
towards the end of the last century has been well characterized,
with a predominance of reports on group A streptococci (GAS)
[1–4]. It spurred an increased attentiveness towards the
epidemiological trends of pyogenic streptococci. Invasive GASClinical Microbiology and Infection © 2014 European Society of Cdisease has accordingly been a notiﬁable disease in Norway
since 1993, allowing close epidemiological monitoring. The
annual incidence has been reported to lie between 1.5 and 3.5
cases per 100 000 for the last decade, although ﬂuctuations
indicating sporadic outbreaks occur from time to time (www.
msis.no). The reported incidence rates in other European
populations and in North America appear to be similar [5,6].
Beta-haemolytic group C and G streptococci (GCS and
GGS) causing human infections are most often of the subspe-
cies Streptococcus dysgalactiae subsp. equisimilis (SDSE). They
share multiple virulence factors with GAS, including the M
protein (encoded by the emm gene) [7]. Furthermore, GCS and
GGS display similar disease manifestations to GAS, includingClin Microbiol Infect 2015; 21: 171–178
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http://dx.doi.org/10.1016/j.cmi.2014.08.019
172 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMInecrotizing fasciitis and toxic shock syndrome [8,9]. The inci-
dence of invasive GCS and GGS-infections, however, is not
systematically registered in Norway.
Several reports worldwide indicate an increase in the SDSE-
related disease burden. Surveys conducted in Great Britain by
the Health Protection Agency showed 100% and 14% increases
in the rates of GCS and GGS bacteraemia, respectively, be-
tween 2006 and 2012 [10]. Rantala et al. found a 2.4-fold rise in
GGS-bacteraemia over a ten-year period in a community in
Finland [11]. Similar developments have been shown in Asia,
Australia and North America [12–14], and an epidemiological
survey in our own community seemed warranted.
Here we describe the demographic and epidemiological
characteristics of invasive GAS infections, and invasive and non-
invasive GCS and GGS-infections in Western Norway over a
15-year period.Materials and methodsStudy population
Haukeland University Hospital (HUH) is a tertiary care hospital
in Bergen, Western Norway. The HUH Microbiological
Department receives clinical microbiological samples from both
hospital and community-based health-care professionals in the
region; the population in the catchment area increased from
360 796 to 427 486 inhabitants during the study period.
As both β-haemolytic group C and G streptococci causing
human infections most frequently belong to the species SDSE,
and the number of group C streptococci was very low, a de-
cision was made to treat them as one group (GCGS) for sta-
tistical purposes. All isolates from the time period 1999 to 2013
associated with invasive GAS and GCGS infections (iGAS and
iGCGS, respectively), along with isolates causing non-invasive
GCGS-infections (nGCGS), were retrospectively identiﬁed
and included. Antibiotic susceptibility pattern, sample date and
material, age and sex were recorded, along with registered
clinical information. Repeatedly positive cultures with the same
organism identiﬁed within 30 days of initial isolation were
considered to be from a single episode.
Invasive disease was deﬁned as isolation of GAS or GCGS
from a normally sterile site (blood, cerebrospinal ﬂuid (CSF),
pleural ﬂuid, bone or synovial ﬂuid), or from a non-sterile site in
combination with necrotizing soft tissue infection (NSTI). NSTI
was deﬁned as necrotizing cellulitis or fasciitis as described
previously [15]. Intra-abdominal and lower airway samples were
classiﬁed as non-invasive, since obtainable clinical data in these
cases generally did not permit assessment of disease invasive-
ness. Systematic evaluation of streptococcal toxic shock
syndrome was impaired for similar reasons. Patients wereClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcategorized as having primary bacteraemia if blood cultures
were positive and no focal source of infection was identiﬁed. The
study underwent an institutional ethics review and approval.
Bacterial isolates, antibiotic susceptibility and
molecular analyses
All isolates displayed large colony size (>0.5 mm in diameter
after 24 hours) and a β-haemolytic reaction on 5% sheep-blood
agar. Serogroup speciﬁcity was determined using a rapid
agglutination test (Oxoid, Basingstoke, Hampshire, UK). For
three culture-negative samples from invasive disease, the
pathogen was identiﬁed by direct 16S rDNA-PCR ampliﬁcation
from the sample material and subsequent sequencing, using
primers and protocol as described previously [16]. Antimi-
crobial susceptibility testing of the invasive isolates had been
performed according to Norwegian guidelines (http://www.unn.
no/afa/). Routine testing for erythromycin susceptibility and
inducible clindamycin resistance was not performed prior to
2004. emm-typing was performed as described elsewhere [17].
Subsets of the isolates had previously been screened for the
presence of virulence genes [18–21].
Statistics
Data were analysed using SPSS PASW STATISTICS, version
21.0 (SPSS Inc, Chicago, IL, USA). Population data for our
catchment area was obtained from Statistics Norway. We
calculated overall annual incidence rates, and by sex and age
group (0–5, 6–15, 16–66, and 67 years). Categorical data
were analysed using Pearson’s chi square test or Fisher’s exact
test as appropriate. Non-parametric data were analysed using
the Mann–Whitney U test or the Kruskal–Wallis test. Time
trends were evaluated by dividing the data into an early cohort
(1999–2003) and a late cohort (2009–2013), and calculating
mean incidence rate ratios (IRR) and a p-value. A two-sided p-
value 0.05 was considered statistically signiﬁcant.ResultsThe 15-year survey period yielded a total of 512 invasive
β-haemolytic streptococcal isolates; 297 GAS (58%), 24 GCS
(5%) and 188 GGS (37%). Three isolates were identiﬁed as
SDSE by direct ampliﬁcation and sequencing of 16S rDNA from
the sample material, and their carbohydrate speciﬁcity is
therefore unknown. The 4935 non-invasive isolates comprised
1044 GCS (21%) and 3891 GGS (79%). The demographic and
clinical characteristics, antibiotic susceptibility patterns and
mortality rates are summarized in Table 1.
Eleven patients had recurrent invasive infections: four caused
by GAS; six by GGS and one patient had an initial episode withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 171–178
TABLE 1. Demographics, clinical characteristics and antibiotic
susceptibility of invasive group A, C and G streptococci and
non-invasive group C and G streptococci in Western
Norway from 1999 to 2013
Characteristics iGAS iGCGS nGCGS
Demographics Years IQR Years IQR Years IQR
Mean age 49.8 34–69 67.3 56–81 43.5 23–63
n (%) n (%) n (%)
0–5 years 21 7.1 0 0 232 4.7
6–15 years 7 2.4 0 0 308 6.2
16–66 years 181 60.9 89 41.4 3371 68.3
67 years 88 29.6 126 58.6 1024 20.7
Male 145 48.8 126 58.6 2615 53.0
Female 152 51.2 89 41.4 2320 47.0
Site of infection
Bacteraemia 39 13.1 42 19.5 0 0
SSTIa 78 26.3 78 36.3 3257 66.0
NSTI 65 21.9 16 7.4 0 0
Bone/joint 30 10.1 55 25.6 0 0
Lower respiratory 29 9.8 8 3.7 0 0
Upper respiratoryb 13 4.4 0 0 1071 21.7
Postpartum/genitalia 28 9.4 5 2.3 282 5.8
Meningitis 7 2.4 0 0 0 0
Endocarditis 4 1.3 6 2.8 0 0
Otherc 4 1.3 5 2.3 325 6.6
Antimicrobial susceptibility
Penicillin 290 100% 204 100% ND ND
Erythromycin 129 91% 150 95% ND ND
Clindamycin 272 95% 202 99% ND ND
30 day mortality 39 13.1 20 9.3 ND ND
Total episodes 297 100 215 100 4935 100
iGAS, invasive group A streptococcal disease; iGCGS, invasive group C or G
streptococcal disease; IQR, inter-quartile range; n, number of cases; ND, no data;
nGCGS, non-invasive group C or G streptococcal disease; NSTI, necrotizing soft
tissue infections; SSTI, skin and soft tissue infections.
aComprised erysipelas, cellulitis, superﬁcial and deep-seated skin and soft-tissue
abscesses, impetigo and wound-infections.
bIncluded tonsillitis, sinusitis, otitis and conjunctivitis.
cComprised urinary tract infections, intra-abdominal infections and mastitis.
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within 6 months in ﬁve cases. Five patients presented with a
new disease-manifestation.
Annual incidence and seasonal variations
The annual incidence for iGAS, iGCGS and nGCGS is pre-
sented in Fig. 1. There was a signiﬁcant increase in iGCGS
incidence from the ﬁrst to the last 5-year period (IRR 1.85,
p <0.001), with annual incidence peaking at 6.3/100 000 in
2013. The iGAS-rates showed marked ﬂuctuations over time,
ranging from 2.7/100 000 (2000) to 8.3/100 000 (1999), but no
statistically signiﬁcant trends were observed (IRR 1.06,
p = 0.69). A signiﬁcant decrease in nGCGS was displayed in the
last 5 year period (IRR 0.81, p <0.001), with annual incidence
falling gradually from 110/100 000 in 2004 to 59/100 000 in
2013.
Both iGAS and iGCGS exhibited seasonal variation. Peak
iGAS incidence occurred during the winter, with 33% and 17%
of the included cases presenting during winter (December–
February) and summer (June–August), respectively. Conversely,
31% of the included iGCGS-cases presented during the summer
months, and only 22% in winter. The nGCGS-incidence did not
vary through the year.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyAge and sex distribution
The age distribution of iGAS, iGCGS and nGCGS infections is
presented in Fig. 2, an increasing incidence with age is seen for
all three categories. However, the median age of the patients in
the iGCGS-cohort was signiﬁcantly higher than in the iGAS-
and nGCGS-cohort (p <0.001), and all iGCGS-patients were
>16 years. The incidence of iGCGS and nGCGS was higher in
men than women, but the difference did not reach statistical
signiﬁcance (p = 0.161 and p = 0.056, respectively).
The annual incidence for different age and sex subgroups is
presented in Fig. 3. Comparing cumulated incidence in the ﬁrst
and last 5-year periods, iGCGS showed a signiﬁcant increase for
men (IRR 2.84, p <0.001), but not forwomen (IRR 1.04, p = 0.88).
The increase was also signiﬁcant for patients aged 16–66 years
(IRR 2.63, p <0.001), and the subgroups of men aged 16–66 years
and 67 years (IRR 2.79, p = 0.005 and IRR 2.85, p = 0.004,
respectively). No subgroups showed an increasing trend for
women. Conversely, nGCGS showed a signiﬁcant decrease for
both men (IRR 0.76, p <0.001) and women (IRR 0.77, p <0.001),
and in all age and sex subgroups. The incidence of iGAS did not
exhibit temporal trends for any age or sex subgroup.
Site of infection
Most invasive isolates were recovered from blood cultures
(74%), the remainder comprising synovial ﬂuid (9%), biopsy
(9%), pus (6%), pleural ﬂuid (1%) and CSF (1%). The com-
monest source of infection was skin and soft-tissue (SSTI) for all
microbial categories, followed by NSTI and primary bacter-
aemia for iGAS; bone/joint-infections and bacteraemia for
iGCGS; and upper respiratory infections for nGCGS.
Mortality
The overall 30-day mortality was 13% for iGAS and 9% for
iGCGS. The mortality rate increased with age, reaching 31% (27/
86) for iGAS and 14% (17/126) for iGCGS in the cohort 67
years. The mortality rate varied across disease groups: for iGAS
it ranged from below 10% in patients suffering from SSTI (8%),
bone/joint-infections (7%) and post-partum/genital infections
(0%), to above 25% in primary bacteraemia (26%), lower respi-
ratory infections (35%) and meningitis (29%). Similarly, for
iGCGS themortality rate ranged from 2% (bone/joint-infections)
and 4% (SSTI) to 19% (primary bacteraemia) and 31% (NSTI).
Interestingly, the mortality for NSTI was higher in iGCGS (5 out
of 16, 31%) than in iGAS (8 out of 65, 12%), although the ﬁnding
did not reach statistical signiﬁcance (p = 0.12).
emm-types
Altogether, 331 out of 512 iGAS and iGCGS isolates were
available for emm-typing. The emm-type distribution is shown in
Fig. 4.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 171–178
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FIG. 1. Annual incidence rates of invasive
group A streptococcal (iGAS), invasive
group C and G streptococcal (iGCGS), and
non-invasive group C and G streptococcal
(nGCGS) infections in Western Norway.
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emm-subtypes were identiﬁed. Twenty-two different emm-
types and 28 subtypes were found among the 122 iGCGS
isolates examined. The predominant emm-types for iGAS and
iGCGS were consistent through the study period, apart from a
temporally localized outbreak of emm11 in 2010–2011.0
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectWe found a mortality rate of 6% (5/83) among iGCGS
caused by the ﬁve most common emm-types, versus 23% (9/39)
in the remaining emm-types (p = 0.012). However, the pro-
portions were reversed for iGAS, revealing a case fatality rate
of 15% (20/137) associated with common emm-types and 5%
(4/74) in rare emm-types (p = 0.045). Indeed, the prevalent0
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FIG. 2. Age-related incidence rates of
invasive group A streptococcal (iGAS),
invasive group C and G streptococcal
(iGCGS), and non-invasive group C and
G streptococcal (nGCGS) infections in
Western Norway from 1999 to 2013.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 171–178
FIG. 3. Sex- and age-speciﬁc annual incidence of invasive group A streptococcal (iGAS), invasive group C and G streptococcal (iGCGS), and non-
invasive group C and G streptococcal (nGCGS) infections in Western Norway.
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(a)
(b)
FIG.4. Distribution of emm-types for
invasive group A streptococcal isolates (A),
and invasive group C and G streptococcal
isolates (B).
176 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIemm-types of emm1.0 and emm3.1 showed the highest mor-
tality rates of 20% (9/44 and 6/29, respectively).DiscussionWe found a highly signiﬁcant increase in the iGCGS-incidence
during the survey-period. This is in accordance with several
other reports over the past decade [11,13,22–24]. Interest-
ingly, on a subgroup level the increase was demonstrated onlyClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectfor men. To our knowledge, this has not been reported in
previous epidemiological iGCGS-studies, although a male pre-
dominance seems to be almost uniformly observed [13,22–25].
There are no signiﬁcant intersexual differences in age distri-
bution to account for the observed phenomenon, but one
could speculate on a relationship to differences in predisposing
comorbidities.
The incidence rate of iGCGS peaked in 2013 at 6.3/100 000,
of which GGS accounted for 5.1/100 000. This is higher than
rates published from our neighbouring countries Denmarkious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 171–178
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(GGS 1.6/100 000), as well as those reported from Canada
(GGS 2.2/100 000) and USA (GGS 3.2/100 000)
[10,11,22,25,26]. These discrepancies may be partly due to
varying surveillance strategies and time periods.
Surprisingly, the incidence of non-invasive GCGS-infections
showed a signiﬁcant decrease over the past decade. Very few
studies have been conducted on nGCGS, and to our knowl-
edge, the ﬁnding has not previously been reported [17, 27]. It is
unclear, though, if this represents a true decrease in nGCGS
morbidity. There have not been any changes in laboratory
methodology that can explain this trend, but a decrease in the
number of samples submitted for analysis by the clinicians
cannot be ruled out.
Similarly, we might also speculate that an increase in microbial
sampling in the hospitals drives the rising incidence of iGCGS.
However, one would expect such an explanation to be reﬂected
also in the incidence of iGAS. Although the incidence of iGAS
exhibited marked temporal ﬂuctuations, there was no signiﬁcant
trend. Furthermore, the number of annually submitted blood
cultures per inhabitant increased only with an IRR of 1.14 (95%
CI, 1.13–1.15) during the survey period whereas iGCGS had an
IRR of 1.85 (95% CI, 1.28–2.70) within the same timeframe.
The main burden of invasive GCGS-disease in our material
was clearly upon the elderly, and the median age of the patients
was signiﬁcantly higher than for iGAS. Furthermore, previous
studies have reported iGCGS to be more common in patients
suffering from chronic diseases or immunosuppression [24, 28].
It is thus plausible that the increase in iGCGS reﬂects the de-
mographic changes we are currently experiencing in the
developed world, with an ageing population and concomitant
increase in comorbidity. The observed discrepancy between
the age distributions of invasive and non-invasive GCGS in-
fections, probably also indicate that the invasive potential of
GCGS is associated with the same host susceptibility factors.
An increase in SDSE virulence, however, has also been recently
proposed, partly based on observations of possible horizontal
transfer of virulence factors from Streptococcus pyogenes [29].
Furthermore, there are several reports on GCGS infections
with severe manifestations, such as NSTI and streptococcal
toxic shock syndrome [8,12,19]. Taken together, these obser-
vations indicate that the increase in iGCGS is multifactorial.
The emm-type distribution in our study conforms closely to
the ﬁndings from our neighbouring countries [22,30]. Similar
emm-proﬁles have also been described in Japan, Australia and
the USA, although slight temporal and geographical differences
are apparent [6,9,13,26]. Rantala et al. recently described a
higher case-fatality rate in SDSE bacteraemia caused by rare
emm-types than that associated with the ﬁve most common
emm-types [30]. It was speculated to be partly due to theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyincreased likelihood of prior exposure to, and development of
protective antibodies against, the most prevalent emm-types.
Likewise, we also found a signiﬁcantly higher mortality rate
associated with rarer GSGS emm-types than with the common
ones. However, this trend was reversed among iGAS, where
the two most common emm-types were associated with the
highest mortality rates. This indicates that the association be-
tween emm-type and mortality is complex.
The observed overall mortality rates for iGAS and iGCGS of
13% and 9%, respectively, is comparable to those documented in
a 14-year survey conducted in Australia [13]. Conversely,
considerably higher rates have been reported in publications
from most other parts of the world [11,23,24,28]. Interestingly,
the mortality rate in patients suffering from NSTI was markedly
higher in iGCGS than iGAS (31% vs 12%). This probably reﬂects
differences in age distribution and underlying comorbidity rather
than bacterial virulence. Caution should be exerted interpreting
the data, however, in light of the low number of cases.
The study is limited by its retrospective design and scarcity
of clinical data. This might have led to misclassiﬁcations of site
of infection, and hampered the interpretation of invasiveness in
samples from non-sterile sites. However, such cases were in
general discarded if insufﬁcient clinical data was obtained. Most
previous studies have included blood-culture isolates only, and
their results are thus not readily comparable with our ﬁndings.
Furthermore, many studies have been based on isolates sub-
mitted to a national surveillance laboratory, which likely leads
to a marked underestimation of incidence. The data from the
present study, based at the primary laboratory and including all
sample materials, probably conforms more closely with the
true disease burden.
In conclusion, the temporal trendof iGCGSundoubtedly seems
to be pointing upwards worldwide. During the past two years, the
incidence of iGCGS has even surpassed that of iGAS in our
community. With an ageing population, it is likely that this trend
will continue. Increased epidemiological attentiveness to iGCGS
seems warranted, with monitoring of further developments.Transparency declarationThe authors declare no conﬂicts of interest.AcknowledgementsWe thank the staff at the microbiological department at Hauke-
landUniversity Hospital for inclusion of isolates and extraction of
statistical data, isolation of bacterial DNA for molecular analysis,
and for providing access to necessary laboratory facilities.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 171–178
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